



# Sodium Nitrite for Out-of-Hospital Cardiac Arrest

---

MICHAEL SAYRE, MD

MEDICAL DIRECTOR, SEATTLE FIRE DEPARTMENT



# Disclosures

---

EMS Medicine Fellowship Director,  
University of Washington

Physio-Control provides a significant grant to partially fund the fellow's salary and benefits.

- I receive travel reimbursement from the fund.

We will discuss a potential indication, not approved by FDA, for an approved drug.



Half of OHCA patients admitted to hospital following restoration of pulses die of brain injury.

## The Hot Dog Study





**Time**

**Electrical**



**Defibrillation**





**Time**

**Hemodynamic**



**CPR + ? Epinephrine**






**Time**

**Metabolic**




?





It's all about the mitochondria.

# Known protective effects of nitric oxide



# Question

---

Will increasing nitric oxide (NO) levels in brain tissue improve neurologic outcome following resuscitation from cardiac arrest?



# Possible approaches

---

Inhaled nitric oxide gas

Drugs that directly increase nitric oxide

- Nitroglycerin, Sodium nitroprusside

Drugs that indirectly increase nitric oxide's effect

- Sildenafil





ELSEVIER

Contents lists available at [ScienceDirect](#)

# Resuscitation

journal homepage: [www.elsevier.com/locate/resuscitation](http://www.elsevier.com/locate/resuscitation)



EUROPEAN  
RESUSCITATION  
COUNCIL

Experimental paper

## Sodium nitroprusside enhanced cardiopulmonary resuscitation improves short term survival in a porcine model of ischemic refractory ventricular fibrillation<sup>☆,☆☆</sup>



Demetris Yannopoulos<sup>a,\*</sup>, Jason A. Bartos<sup>a</sup>, Stephen A. George<sup>a</sup>, George Sideris<sup>b</sup>, Sebastian Voicu<sup>b</sup>, Brett Oestreich<sup>a</sup>, Timothy Matsuura<sup>c</sup>, Kadambari Shekar<sup>c</sup>, Jennifer Rees<sup>a</sup>, Tom P. Aufderheide<sup>d</sup>

<sup>a</sup> Division of Cardiology, Department of Medicine, University of Minnesota, Minneapolis, MN, United States

<sup>b</sup> Department of Cardiology, Inserm U942, Lariboisiere Hospital, AP-HP, Paris Diderot University, Paris, France

<sup>c</sup> Department of Integrated Biology & Physiology, University of Minnesota, Minneapolis, MN, United States

<sup>d</sup> Department of Emergency Medicine, Medical College of Wisconsin, Milwaukee, WI, United States

Sodium  
nitroprusside  
is not  
affordable

HOME SEARCH

The New York Times

Will By? Use By? Grocery  
Industry Moves to  
Simplify Labels



ECONOMIC TRENDS  
While We're Distracted by  
the Drama, the Economy  
Seems to Be Taking Off



Wall Street Record Rally  
Falters as Banks, Health  
Stocks Weigh



Investors Look Past  
Headlines as Bull Market  
Roars Ahead



Asian Conglomerat  
Flush With Cash, St  
U.S. Fund Deals

BUSINESS DAY

## *Valeant Promised Price Breaks on Drugs. Heart Hospitals Are Still Waiting.*

By KATIE THOMAS MAY 11, 2016



Outrage over the cost of the two drugs began in February of last year, when Valeant bought Nitropress and Isuprel and immediately raised their prices. In 2015, the price of Nitropress, an emergency blood-pressure drug, went from \$215 a vial to \$881, an increase of more than 300 percent, according to the Cleveland Clinic. Isuprel, which treats [abnormal heart rhythms](#), went from \$180 to \$1,472 a vial, a 718 percent increase.


Can a  
different FDA  
approved  
drug serve as  
a source for  
nitric oxide?




Nitrite

Nitrate








# The bad

---

Nitrite functions as a food preservative.

FDA regulates it.

- Nitrosamines produced during acidic/high heat



Beet Juice: 22-50 mg nitrite


---


## **A Single Dose of Beetroot Juice Enhances Cycling Performance in Simulated Altitude**

DAVID J. MUGGERIDGE<sup>1,2</sup>, CHRISTOPHER C. F. HOWE<sup>2</sup>, OWEN SPENDIFF<sup>2</sup>, CHARLES PEDLAR<sup>3</sup>,  
PHILIP E. JAMES<sup>4</sup>, and CHRIS EASTON<sup>1,2</sup>


<sup>1</sup>*Institute for Clinical Exercise and Health Science, University of the West of Scotland, Hamilton, Scotland, UNITED KINGDOM;*  
<sup>2</sup>*School of Life Sciences, Kingston University, Kingston upon Thames, England, UNITED KINGDOM;* <sup>3</sup>*School of Sport, Health and Applied Science, St Mary's University College, Twickenham, England, UNITED KINGDOM;* and <sup>4</sup>*Wales Heart Research Institute, Cardiff University School of Medicine, Cardiff, Wales, UNITED KINGDOM*

# What happens to nitrite levels during cardiac arrest?





# Mouse cardiac arrest model



**Figure 6. Nitrite therapy improves survival after cardiac arrest**

After successful resuscitation, animals died between 1 and 6 hours after CPR. Nitrite therapy resulted in improved survival to 22 hours post-CPR compared to placebo (\*,  $p=0.033$ ;  $n=28/27$  for placebo/nitrite groups).

# SNOCAT Study Hypothesis

---

Infusion of sodium nitrite during resuscitation (before ROSC) will improve neurologic outcome and survival after cardiac arrest.



# SNOCAT: Sodium nitrite out of hospital cardiac arrest trial

---

## Phase 1 (dose finding and safety trial)

- n=100, expect 40 to survive to ED admission
- Open label, start dose of 25 mg.
- Achieve plasma level of 10  $\mu\text{M}$ ?

# Eligibility

---

Out-of-hospital cardiac arrest (VF, non-VF)

Unconscious/not following commands

IV access/IO

Not in the three P's: Pregnant, Pediatric, Prisoners



# Safety Data Being Collected

---

Re-arrest

Use of vasopressors: norepinephrine or epinephrine infusions

Blood Draws for NO<sub>2</sub> levels at ED or in field

- For Harborview Medical Center only additional draws at 20, 40, 60, 80, 100, 120 minute time points

# Endpoints

---

Plasma level of nitrite at hospital, ED arrival

Safety: re-arrest, use of pressors

N=100 (expect 40 to be admitted to ED)



# SNOCAT: Sodium nitrite out of hospital cardiac arrest trial

---

## Phase 2 (safety and efficacy)

- n=1000, expect 400 to survive to ED
- Randomized/blinded
- Primary endpoint: Survival to ED (safety endpoint)
- Secondary endpoint: Survival to discharge

# SNOCAT Investigators

---

Francis Kim

Peter Kudenchuk

Graham Nichol

Michele Olsufka

Michael Sayre

Sue Scruggs

Chuck Maynard

Susanne May



# Safety

---

Low risk for hypotension

No risk for methemoglobin

“Restores nitrite level to baseline”

Given post-arrest at doses up to 9 mg, no significant effects

Effect during resuscitation unknown?

# The good


---

Increases NO levels in blood (blood pressure lowering effects)


May protect blood vessels

Found in supplements (increase endurance)





# Ischemia/reperfusion




Superoxide

Nitric oxide  
Hydrogen sulfide  
Carbon monoxide



	<b>NO</b>	<b>CO</b>	<b>H<sub>2</sub>S</b>
Toxic Gas?	Exhaust, air pollution	Air pollution	Sewers, swamps
Produced by cells	Nitric oxide synthase (NOS) nitrite	Made from hemoglobin	Synthesized from L-cysteine
Vascular effects	Vasodilates	Vasodilates	Vasodilates
Anti-inflammatory effects	Yes	Yes	Yes
Mitochondrial	Decrease	Decrease	Decrease





# NO-ischemia

---

Protective role of nitric oxide in ischemia reperfusion  
(liver, heart, brain)

- Genetic overexpression studies
- Drug (NO-donor) (different structures)

# NO production is reduced during ischemia


---

Nitric oxide production by NOS requires oxygen (not suitable for ischemia)

Nitric oxide production requires cofactors (limited during ischemia)



## The NO-nitrite-nitrate pool



Dezfulian, C. et al. *Cardiovasc Res* 2007 75:327-338;  
 doi:10.1016/j.cardiores.2007.05.001

Cardiovascular  
 Research



	Mouse 12 min asystolic arrest 3d post-arrest histology (n=3)		Rat 8 min asphyxial arrest 7d post-arrest histology (n=3)		Rat 8 min asphyxial arrest 7d post-arrest histology (n=6)	
Sample H&E histology; CA1 region of hippocampus						
Dose Delivered (μmol/kg)	Placebo	1.85	Placebo	13.3	Placebo	53.2
Pre-arrest Blood Nitrite (μM)	1.146 ± 0.213 (*; n=5)	1.146 ± 0.213 (*; n=5)	0.981 ± 0.833 (n=3)	0.811 ± 0.134 (n=3)	1.082 ± 0.340 (n=6)	1.133 ± 0.347 (n=6)
Post-arrest (pre-drug) Blood Nitrite (μM)	-	-	0.937 ± 0.741	0.904 ± 0.135	1.150 ± 0.381	0.836 ± 0.189
Post-arrest (post-drug) Blood Nitrite (μM)	0.644 ± 0.137	1.014 ± 0.136 (‡)	0.798 ± 0.398	25.835 ± 7.250 (‡)	0.953 ± 0.340	179.429 ± 53.974 (‡)
Neuronal Death (%)	57.7 ± 24.1	17.1 ± 5.7 (†)	50.3 ± 7.3	40.4 ± 10.1	15.1 ± 5.9	23.7 ± 8.6 (†)

**Figure 3. Nitrite Therapy after Cardiac Arrest: Dose Titration with Brain Histology and Blood Nitrite Levels**

Results of three separate studies examining different doses of nitrite given at the initiation of CPR (mice) or 5 minutes after the start of CPR as a 20 minute infusion (rats). In the mouse studies, \* indicates that only a single blood draw was performed, pre-arrest levels are derived from a single sham group that did not receive cardiac arrest and there is no post-arrest pre-drug level since the drug was given at the initiation of CPR. In the hematoxylin and eosin stained brain slices, the bar indicates 40 micrometer distance. †, indicates  $p < 0.05$  and ‡ indicates  $p < 0.01$ . Note that nitrite depletion was seen in the mouse but not rat models. Consistent with other animals studies, the low and moderate doses of nitrite which produced blood levels of 1 and 25.8 uM appear to be neuroprotective but not the highest dose which appeared to cause harm.




# IV nitrite in acute ST elevation MI

---

229 pts randomized (70 uM, 5 mg over 5 minutes) or placebo before coronary intervention

Mean nitrite level at randomization (.70 uM)

Nitrite (1.42 uM) vs. placebo (.18 uM) 5 min after completion of infusion



Siddiqi N et al. Eur Heart J 2014;35:1255-1262

# Clinical-nitrites

---





Peripheral arterial disease (oral doses 40-80 mg)-2014


CHF (17.5 mg)-2015


Organ preservation for transplant


Cardiac arrest (post) (1-14 mg)















# Ischemia/reperfusion



# Ischemia/reperfusion

